Our clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make the difference in their everyday lives.
Shield Therapeutics is a specialty pharmaceutical company focused on the development and commercialisation of late‑stage, hospital‑focused pharmaceuticals which address areas of unmet medical need.
Find out moreFeraccru®/Accrufer® is a novel oral product that addresses the needs of patients who cannot tolerate existing oral iron products and offers a clear alternative to IV iron therapy.
Find out moreThe content of all investor relations materials contained on this website are deemed to be correct at the time of issue/publication.
RT @Edison_Inv_Res: @ShieldTx has announced the appointment of a new CEO, Greg Madison, with effect from 1 June 2021. $STX #research #healt…
RT @proactive_UK: $STX Shield Therapeutics appoints CEO with "deep knowledge" of the iron deficiency market https://t.co/2n1jonBaL6 @shiel…
RT @WalbrookPR: Shield Therapeutics plc (LSE: #STX, @ShieldTx) announces that Greg Madison has been appointed as Chief Executive Officer (C…
